Literature DB >> 7334388

Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease.

A J Lees, G M Stern.   

Abstract

The progress of 50 previously untreated patients with idiopathic Parkinson's disease taking maximum tolerated doses of bromocriptine is compared with patients who had taken levodopa. Twenty-eight of the bromocriptine treated patients showed sustained benefit for at least one year and in five this persisted longer than five years. Fewer of the late complications of levodopa therapy occurred in those taking bromocriptine; drug-induced dyskinesia was seen in only one patient and oscillations in performance were not observed. There was a tendency for deterioration to develop after two years treatment when patients then failed to respond well to levodopa. It was not possible to extend the period of effective control of disabilities by first giving bromocriptine.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7334388      PMCID: PMC491206          DOI: 10.1136/jnnp.44.11.1020

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  7 in total

1.  A method for evaluating disability in patients with Parkinson's disease.

Authors:  G J CANTER; R DE LA TORRE; M MIER
Journal:  J Nerv Ment Dis       Date:  1961-08       Impact factor: 2.254

2.  Critical analysis of the disability in Parkinson's disease.

Authors:  D D Webster
Journal:  Mod Treat       Date:  1968-03

3.  Bromocriptine in Parkinson's disease.

Authors:  G Stern; A Lees
Journal:  Br J Hosp Med       Date:  1978-12

4.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

5.  Bromocriptine and domperidone in the treatment of Parkinson disease.

Authors:  N Quinn; A Illas; F Lhermitte; Y Agid
Journal:  Neurology       Date:  1981-06       Impact factor: 9.910

6.  Bromocriptine in parkinsonism. A long-term study.

Authors:  A J Lees; S Haddad; K M Shaw; L J Kohout; G M Stern
Journal:  Arch Neurol       Date:  1978-08

7.  Long-term treatment of parkinsonism with bromocriptine.

Authors:  D B Calne; C Plotkin; A C Williams; J G Nutt; A Neophytides; P F Teychenne
Journal:  Lancet       Date:  1978-04-08       Impact factor: 79.321

  7 in total
  23 in total

Review 1.  The on-off phenomenon.

Authors:  A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

Review 2.  Current drug therapy for Parkinson's disease. A review.

Authors:  R J Coleman
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

3.  Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.

Authors:  A Colzi; K Turner; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-05       Impact factor: 10.154

4.  Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease.

Authors:  B Henry; J M Brotchie
Journal:  Drugs Aging       Date:  1996-09       Impact factor: 3.923

5.  Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys.

Authors:  S Boyce; N M Rupniak; M J Steventon; S D Iversen
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 6.  Therapeutic applications of bromocriptine in endocrine and neurological diseases.

Authors:  K Y Ho; M O Thorner
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

Review 7.  Parkinson's disease in 1984: an update.

Authors:  A E Lang; R D Blair
Journal:  Can Med Assoc J       Date:  1984-11-01       Impact factor: 8.262

Review 8.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

9.  Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.

Authors: 
Journal:  BMJ       Date:  1993-08-21

Review 10.  Current status of dopamine agonists in Parkinson's disease management.

Authors:  J L Montastruc; O Rascol; J M Senard
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.